The 36 references in paper L.V. Gerasimov , V. Samorukov Yu., V. Moroz V., G. Ivanova P., Л. Герасимов В., В. Саморуков Ю., В. Мороз В, Г. Иванова П. (2012) “Применение эритропоэтина у больных с травмой и кровопотерей // Use of Erythropoietin in Patients with Injury and Blood Loss” / spz:neicon:reanimatology:194

1
Загреков В. И.,Таранюк А. В.,Максимов Г. А.,Ежов Ю. И. Предопе! рационная стимуляция эритропоэза у больных с анемией. Общая реаниматология. 2010; 7 (2): 56—61.
(check this in PDF content)
2
Corwin H. L.,Gettinger A.,Pearl R. G.,Fink M. P.,Levy M. M.,Abraham E., MacIntyre N. R.,Shabot M. M.,Duh M. S.,Shapiro M. J. The CRIT Study: Anemia and blood transfusion in the critically ill — current clin! ical practice in the United States. Crit. Care Med. 2004; 32 (1): 39—52.
(check this in PDF content)
3
Huber!Wagner S.,Qvick M.,Mussack T.,Euler E.,Kay M. V.,Mutschler W., Kanz K. G. Massive blood transfusion and outcome in 1062 polytrauma patients: a prospective study based on the Trauma Registry of the German Trauma Society. Vo x S a n g. 2007; 92 (1): 69—78.
(check this in PDF content)
4
Vincent J. L.,Baron J. F.,Reinhart K.,Gattinoni L.,Thijs L.,We b b A., Meier!Hellmann A.,Nollet G.,Peres!Bota D. Anemia and blood transfu! sion in critically ill patients. JAMA. 2002; 288 (12): 1499—1507.
(check this in PDF content)
5
Offner P. J.,Moore E. E.,Biffl W. L.,Johnson J. L.,Offner P. J.,Moore E. E., Biffl W. L.,Johnson J. L. Increased rate of infection associated with transfusion of old blood after severe injury. Arch. Surg.2002; 137 (6): 711—716.
(check this in PDF content)
6
Gabriel A.,Kozek S.,Chiari A.,Fitzgerald R.,Grabner C.,Geissler K., Zimpfer M.,Stockenhuber F.,Bircher N. G. High!dose recombinant human erythropoietin stimulates reticulocyte production in patients with multi! ple organ dysfunction syndrome. J. Tr a u m a. 1998; 44 (2): 361—367.
(check this in PDF content)
7
Georgopoulos D.,Matamis D.,Routsi C.,Michalopoulos A.,Maggina N., Dimopoulos G.,Zakynthinos E.,Nakos G.,Thomopoulos G.,Mandragos K., Maniatis A. Recombinant human erythropoietin therapy in critically ill patients: a dose!response study [ISRCTN48523317]. Crit. Care. 2005; 9 (5): R508—R515.
(check this in PDF content)
8
Silver M.,Corwin M. J.,Bazan A.,Gettinger A.,Enny C.,Corwin H. L. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long!term acute care facility: a randomized, double!blind, placebo!controlled trial. Crit. Care Med. 2006; 34 (9): 2310—2316.
(check this in PDF content)
9
Still J. M. Jr.,Belcher K.,Law E. J.,Thompson W.,Jordan M.,Lewis M., Saffle J.,Hunt J.,Purdue G. F.,Wa y m a c k J. P. A double!blinded prospec! tive evaluation of recombinant human erythropoietin in acutely burned patients. J. Tr a u m a. 1995; 38 (2): 233—236.
(check this in PDF content)
10
Iperen C. E.,Gaillard C. A.,Kraaijenhagen R. J.,Braam B. G.,Marx J. J., van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit. Care Med. 2000; 28 (8): 2773—2778.
(check this in PDF content)
11
Vincent J. L.,Spapen H. D.,Creteur J.,Piagnerelli M.,Hubloue I.,Diltoer M., Roman A.,Stevens E.,Ve r c a m m e n E.,Beaver J. S. Pharmacokinetics and pharmacodynamics of once!weekly subcutaneous epoetin alfa in criti! cally ill patients: results of a randomized, double!blind, placebo!con! trolled trial. Crit. Care Med. 2006; 34 (6): 1661—1667.
(check this in PDF content)
12
Corwin H. L.,Gettinger A.,Pearl R. G.,Fink M. P.,Levy M. M.,Shapiro M. J., Corwin M. J.,Colton T. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002; 288 (22): 2827—2835.
(check this in PDF content)
13
Corwin H. L.,Gettinger A.,Fabian T. C.,May A.,Pearl R. G.,Heard S.,An R., Bowers P. J.,Burton P.,Klausner M. A.,Corwin M. J. Efficacy and safety of epoetin alfa in critically ill patients. N. Engl. J. Med. 2007; 357 (10): 965—976.
(check this in PDF content)
14
Napolitano L. M.,Fabian T. C.,Kelly K. M.,Bailey J. A.,Block E. F., Langholff W.,Enny C.,Corwin H. L. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J. Tr a u m a. 2008; 65 (2): 285—297.
(check this in PDF content)
15
Hobisch!Hagen P.,Wiedermann F.,Mayr A.,Fries D.,Jelkmann W.,Fuchs D., Hasibeder W.,Mutz N.,Klingler A.,Schobersberger W. Blunted erythro! poietic response to anemia in multiply traumatized patients. Crit. Care Med. 2001; 29 (4): 743—747.
(check this in PDF content)
16
Vialet R.,Ve n t r e ́C.,Leone M.,Conforto C.,Martin C. Erythropoietin measurements in severely traumatized patients. Acta Anaesthesiol. Scand. 2008; 52 (5): 601—604.
(check this in PDF content)
17
Jelkmann W.,Pagel H.,Wo l f f M.,Fandrey J. Monokines inhibiting ery! thropoietin production in human hepatoma cultures and isolated per! fused rat kidneys. Life Sci. 1992; 50 (4): 301—308.
(check this in PDF content)
18
Jelkmann W. Proinflammatory cytokines lowering erythropoietin pro! duction. J. Interferon Cytokine Res. 1998; 18 (8): 555—559.
(check this in PDF content)
19
Hoynck van Papendrecht M. A.,Jeekel H.,Busch O. R.,Marquet R. L. Efficacy of recombinant erythropoietin for stimulating erythropoiesis after blood loss and surgery. An experimental study in rats. Eur. J. Surg. 1992; 158 (2): 83—87.
(check this in PDF content)
20
Jones K. B.,Anderson D. W.,Longmore G. D. Effects of recombinant hematopoietins on blood!loss anemia in mice. Iowa Orthop. J. 2005; 25: 129—134.
(check this in PDF content)
21
Cooper A. C.,Breen C. P.,Vyas B.,Ochola J.,Kemeny D. M.,Macdougall I. C. Poor response to recombinant erythropoietin is associated with loss of T! lymphocyte CD28 expression and altered interleukin!10 production. Nephrol. Dial. Tr a n s p l a n t. 2003; 18 (1): 133—140.
(check this in PDF content)
22
Dellinger R. P.,Carlet J. M.,Masur H.,Gerlach H.,Calandra T.,Cohen J., Gea!Banacloche J.,Keh D.,Marshall J. C.,Parker M. M.,Ramsay G., Zimmerman J. L.,Vincent J. L.,Levy M. M. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004; 30 (4): 536—555.
(check this in PDF content)
23
Elliot J. M.,Virankabutra T.,Jones S.,Ta n u d s i n t u m S.,Lipkin G.,To d d S., Bion J. Erythropoietin mimics the acute phase response in critical ill! ness. Crit. Care. 2003; 7 (3): R35—R40.
(check this in PDF content)
24
Eschbach J. W.,Kelly M. R.,Haley N. R.,Abels R. I.,Adamson J. W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N. Engl. J. Med. 1989; 321 (3): 158—163.
(check this in PDF content)
25
Erslev A. J. In vitroproduction of erythropoietin by kidneys perfused with a serum!free solution. Blood. 1974; 44 (1): 77—85.
(check this in PDF content)
26
Bauer C.,Kurtz A.,Eckardt K. U.,Ta n n a h i l l L. Regulation oferythropoi! etin synthesis. Nephron. 1989; 51 Suppl 1: 3—10.
(check this in PDF content)
27
Roberts D.,Smith D. J. Erythropoietin: induction of synthesis to signal transduction. J. Mol. Endocrinol. 1994; 12 (2): 131—148.
(check this in PDF content)
28
Tr y b a M. Epoetin alfa plus autologous blood donation and normov! olemic hemodilution in patients scheduled for orthopedic or vascular surgery. Semin. Hematol. 1996; 33 (2 Suppl 2): 34—36.
(check this in PDF content)
29
Darveau M.,Notebaert E.,Denault A. Y.,Williamson D. R.,Albert M., Be ́lisle S.,Lachaine J. Erythropoietic response to two epoetin alfa regi! mens in critically ill patients: a pilot study. Pharmacotherapy. 2006; 26 (11): 1587—1594.
(check this in PDF content)
30
Arroliga A. C.,Guntupalli K. K.,Beaver J. S.,Langholff W.,Marino K., Kelly K. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Crit. Care Med. 2009; 37 (4): 1299—1307.
(check this in PDF content)
31
Pieracci F. M.,Eachempati S. R.,Christos P. J.,Barie P. S.,Mushlin A. I. Diagnosis and management of iron!related anemias in critical illness. Crit. Care Med. 2006; 34 (7): 1898—1905.
(check this in PDF content)
32
Ball A. M.,Winstead P. S. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. Pharmacotherapy. 2008; 28 (11): 1383—1390.
(check this in PDF content)
33
Орлов Ю. П.,Иванов А. В.,Долгих В. Т.,Лукач В. Н. Нарушения об! мена железа в патогенезе критических состояний (эксперименталь! ное исследование). Общая реаниматология. 2011; 7 (5): 15—19.
(check this in PDF content)
34
Tu r a g a K. K.,Sugimoto J. T.,Forse R. A. A meta!analysis of randomized controlled trials in critically ill patients to evaluate the dose!response effect of erythropoietin. J. Intensive Care Med. 2007; 22 (5): 270—282.
(check this in PDF content)
35
Muñoz!Langa J. M.,Juan Vidal O.,Olmos S.,Albert A.,Molins C.,Campos J., Bosch C.,Carañana V.,Alberola Candel V.,Almenar!Cubells D. Predictive model of response to epoetin!alfa in anemic patients with solid tumors receiving chemotherapy: Results from a multicenter prospective study. ASCO Meeting Abstracts, May 2008; 26: 20607.
(check this in PDF content)
36
Lundy J. B.,Hetz K.,Chung K. K.,Renz E. M.,White C. E.,King B. T., Huzar T.,Wo l f S. E.,Blackbourne L. H. Outcomes with the use of recom! binant human erythropoietin in critically ill burn patients. Am. Surg. 2010; 76 (9): 951—956.
(check this in PDF content)